September 09, 2025 11:00 ET | Source: Chiesi Global Rare Diseases Results presented focus on clinical insights on Fabry disease…
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American…
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to…
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsiesData include an…
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing…
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in…
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of…
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase…
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the…